Journal
JOURNAL OF MEDICAL VIROLOGY
Volume 94, Issue 1, Pages 279-286Publisher
WILEY
DOI: 10.1002/jmv.27316
Keywords
coronaVac; immunogenicity; inactivated virus vaccine; neutralizing antibody; SARS-CoV-2 antibody
Categories
Funding
- Baskent University
Ask authors/readers for more resources
This study evaluated antibody levels after inactivated virus vaccination, finding that individuals previously infected with COVID-19 had higher antibody levels and longer duration of antibody response after a single vaccine dose. A positive correlation between IgGsp antibody titers and neutralizing capacity was also observed, suggesting that quantitative IgGsp values may reflect vaccine neutralization capacity.
Vaccines have been seen as the most important solution for ending the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study is to evaluate the antibody levels after inactivated virus vaccination. We included 148 healthcare workers (74 with prior COVID-19 infection and 74 with not). They received two doses of inactivated virus vaccine (CoronaVac). Serum samples were prospectively collected three times (Days 0, 28, 56). We measured SARS-CoV-2 IgGsp antibodies quantitatively and neutralizing antibodies. After the first dose, antibody responses did not develop in 64.8% of the participants without prior COVID-19 infection. All participants had developed antibody responses after the second dose. We observed that IgGsp antibody titers elicited by a single vaccine dose in participants with prior COVID-19 infection were higher than after two doses of vaccine in participants without prior infection (geometric mean titer: 898 and 607 AU/ml). IgGsp antibodies, participants with prior COVID-19 infection had higher antibody levels as geometric mean titers at all time points (p < 0.001). We also found a positive correlation between IgGsp antibody titers and neutralizing capacity (r(s) = 0.697, p < 0.001). Although people without prior COVID-19 infection should complete their vaccination protocol, the adequacy of a single dose of vaccine is still in question for individuals with prior COVID-19. New methods are needed to measure the duration of protection of vaccines and their effectiveness against variants as the world is vaccinated. We believe quantitative IgGsp values may reflect the neutralization capacity of some vaccines.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available